Leukemia (AML & MDS): Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and
Acute Myeloid Leukemia (AML) Disease Registry
What are the patterns of diagnosis, treatment and outcomes including disease progression
and survival; what are the patterns for quality of life in patients newly diagnosed
with Lower-Risk MDS, Higher-Risk MDS, ICUS or AML and what effect does different treatments
have on a patient's disease and on their quality of life?
Basic Study Information
Purpose:Location: Cancer Center
This study is observational. An observational disease registry study means that only
information about your disease and medical treatment that your study doctor is already
prescribing as part of your standard medical care is collected. Standard medical care
is the treatment normally given for a certain condition or illness.
You will continue with your standard medical care and continue with any medicines
you are now taking, office visits and laboratory testing according to the normal routine
practices of your treating or study doctor(s). No additional medication, or payment
for medication, is provided as part of this study. There is no investigational drug
involved in this study. There will be no additional study visits, procedures, or
testing required for this study. We will only collect this information as it relates
to the standard medical care you are receiving. If you give your consent to participate
in this study, your study doctor will inform your treating doctor(s), if applicable,
that you are taking part in this study.
Study Reference #: ICHR17065
Lead Researcher (Principal Investigator)
Lead Researcher: Jason Mendler
Study Contact InformationStudy Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Additional Study Details
Learn More About These Conditions
More information about Myeloid leukemia, acute
Trial Not Found
The study you are looking for is not active at this time.
Return to Search